Bicycle Therapeutics Net Income 2018-2021 | BCYC

Bicycle Therapeutics net income from 2018 to 2021. Net income can be defined as company's net profit or loss after all revenues, income items, and expenses have been accounted for.
Bicycle Therapeutics Annual Net Income
(Millions of US $)
2020 $-51
2019 $-31
2018 $-22
2017 $-16
Bicycle Therapeutics Quarterly Net Income
(Millions of US $)
2021-09-30 $-15
2021-06-30 $-18
2021-03-31 $-16
2020-12-31 $-17
2020-09-30 $-10
2020-06-30 $-12
2020-03-31 $-11
2019-12-31 $-4
2019-09-30 $-9
2019-06-30 $-10
2019-03-31 $-7
2018-12-31 $-7
2018-09-30 $-8
2018-06-30 $-5
2018-03-31 $-3
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.424B $0.010B
Bicycle Therapeutics plc is a clinical-stage biopharmaceutical company. It is focused on developing medicines, referred to as Bicycles(R) for diseases which are underserved by existing therapeutics. Bicycle Therapeutics plc is based in Cambridge, United Kingdom.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $144.122B 9.11
Bio-Rad Laboratories (BIO.B) United States $18.677B 37.90
QIAGEN (QGEN) Netherlands $11.053B 18.72
Biohaven Pharmaceutical Holding (BHVN) United States $8.002B 0.00
Emergent Biosolutions (EBS) United States $2.809B 10.10
Arcus Biosciences (RCUS) United States $2.516B 0.00
Myovant Sciences (MYOV) United Kingdom $1.432B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.186B 0.00
Zymeworks (ZYME) Canada $0.697B 0.00
Ambrx Biopharma (AMAM) United States $0.230B 0.00
SQZ Biotechnologies (SQZ) United States $0.229B 0.00
Enzo Biochem (ENZ) United States $0.160B 20.69